Tauroursodeoxycholic acid: relieving the pathogenesis of HFE C282Y hereditary hemochromatosis.
Lawless
Matthew W
MW
Mankan
Arun K
AK
Ryan
Anthony W
AW
Norris
Suzanne
S
D000975:Antioxidants / Q000627:therapeutic use*; D003545:Cysteine; D004721:Endoplasmic Reticulum / Q000378:metabolism; D006432:Hemochromatosis / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006720:Homozygote; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics*; D009154:Mutation; D017382:Reactive Oxygen Species / Q000378:metabolism; D013655:Taurochenodeoxycholic Acid / Q000627:therapeutic use*; D014443:Tyrosine
D000975:Antioxidants; C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D017382:Reactive Oxygen Species; D014443:Tyrosine; D013655:Taurochenodeoxycholic Acid; C031655:ursodoxicoltaurine; D003545:Cysteine